ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years
Zheng Li
Matched on ORCID iD 0000-0002-9828-5475; OpenAlex author ID A5100415037. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 1, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 31
2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper · 2026: 1 paper
Papers 5
- SUZ12 promotes pancreatic ductal adenocarcinoma progression and chemoresistance by epigenetically silencing NCOA4-induced ferroptosis. Co-author DOI 10.3724/abbs.2025215↗
- Acyl-CoA thioesterase 8 induces gemcitabine resistance via regulation of lipid metabolism and antiferroptotic activity in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41401-025-01477-y↗
- YBX1 as a therapeutic target to suppress the LRP1-β-catenin-RRM1 axis and overcome gemcitabine resistance in pancreatic cancer. Last author DOI 10.1016/j.canlet.2024.217197↗
- Short-Term Outcomes Following Laparoscopic vs Open Pancreaticoduodenectomy in Patients With Pancreatic Ductal Adenocarcinoma: A Randomized Clinical Trial. Co-author DOI 10.1001/jamasurg.2023.5210↗
- Pevonedistat Suppresses Pancreatic Cancer Growth via Inactivation of the Neddylation Pathway. First author DOI 10.3389/fonc.2022.822039↗
Closest collaborators
The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Xiaowu Xu · 3 shared papers, 2024–2026 · strength 0.67
- Paper SUZ12 promotes pancreatic ductal adenocarcinoma progression and chemoresistance by epigenetically silencing NCOA4-induc… DOI 10.3724/abbs.2025215↗
- Paper Acyl-CoA thioesterase 8 induces gemcitabine resistance via regulation of lipid metabolism and antiferroptotic activity … DOI 10.1038/s41401-025-01477-y↗
- Paper YBX1 as a therapeutic target to suppress the LRP1-β-catenin-RRM1 axis and overcome gemcitabine resistance in pancreatic… DOI 10.1016/j.canlet.2024.217197↗
- Borui Li · 3 shared papers, 2024–2026 · strength 0.67
- Paper SUZ12 promotes pancreatic ductal adenocarcinoma progression and chemoresistance by epigenetically silencing NCOA4-induc… DOI 10.3724/abbs.2025215↗
- Paper Acyl-CoA thioesterase 8 induces gemcitabine resistance via regulation of lipid metabolism and antiferroptotic activity … DOI 10.1038/s41401-025-01477-y↗
- Paper YBX1 as a therapeutic target to suppress the LRP1-β-catenin-RRM1 axis and overcome gemcitabine resistance in pancreatic… DOI 10.1016/j.canlet.2024.217197↗
- Shunrong Ji · 4 shared papers, 2022–2025 · strength 0.67
- Paper Acyl-CoA thioesterase 8 induces gemcitabine resistance via regulation of lipid metabolism and antiferroptotic activity … DOI 10.1038/s41401-025-01477-y↗
- Paper YBX1 as a therapeutic target to suppress the LRP1-β-catenin-RRM1 axis and overcome gemcitabine resistance in pancreatic… DOI 10.1016/j.canlet.2024.217197↗
- Paper Pevonedistat Suppresses Pancreatic Cancer Growth via Inactivation of the Neddylation Pathway. DOI 10.3389/fonc.2022.822039↗
- Qifeng Zhuo · 3 shared papers, 2022–2025 · strength 0.55
- Paper Acyl-CoA thioesterase 8 induces gemcitabine resistance via regulation of lipid metabolism and antiferroptotic activity … DOI 10.1038/s41401-025-01477-y↗
- Paper YBX1 as a therapeutic target to suppress the LRP1-β-catenin-RRM1 axis and overcome gemcitabine resistance in pancreatic… DOI 10.1016/j.canlet.2024.217197↗
- Paper Pevonedistat Suppresses Pancreatic Cancer Growth via Inactivation of the Neddylation Pathway. DOI 10.3389/fonc.2022.822039↗
- Xianjun Yu · 3 shared papers, 2022–2024 · strength 0.46
- Paper YBX1 as a therapeutic target to suppress the LRP1-β-catenin-RRM1 axis and overcome gemcitabine resistance in pancreatic… DOI 10.1016/j.canlet.2024.217197↗
- Paper Pevonedistat Suppresses Pancreatic Cancer Growth via Inactivation of the Neddylation Pathway. DOI 10.3389/fonc.2022.822039↗
- Paper Short-Term Outcomes Following Laparoscopic vs Open Pancreaticoduodenectomy in Patients With Pancreatic Ductal Adenocarc… DOI 10.1001/jamasurg.2023.5210↗
- Xuemin Chen · 1 shared paper, 2026 · strength 0.27
- Lei Yin · 1 shared paper, 2026 · strength 0.27
- Xiaowu Xu · 2 shared papers, 2022–2023 · strength 0.27
- Di Wu · 1 shared paper, 2025 · strength 0.21
- Chenjie Zhou · 1 shared paper, 2025 · strength 0.21
- Yi Qin · 1 shared paper, 2025 · strength 0.21
- Faliang Xing · 1 shared paper, 2024 · strength 0.20
- Chenjie Zhou · 1 shared paper, 2024 · strength 0.20
- Ye Zeng · 1 shared paper, 2022 · strength 0.15
- Heli Gao · 1 shared paper, 2022 · strength 0.15
- Junfeng Xu · 1 shared paper, 2022 · strength 0.15
- Wenyan Xu · 1 shared paper, 2022 · strength 0.15
- Wensheng Liu · 1 shared paper, 2022 · strength 0.15
- Zhenxiong Zhang · 1 shared paper, 2023 · strength 0.12
- Hongqin Ma · 1 shared paper, 2023 · strength 0.12
- Shutao Pan · 1 shared paper, 2023 · strength 0.12
- Xuemin Chen · 1 shared paper, 2023 · strength 0.12
- Yichen Tang · 1 shared paper, 2023 · strength 0.12
- Jingdong Li · 1 shared paper, 2023 · strength 0.12
- Min Wang · 1 shared paper, 2023 · strength 0.12
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.